A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum

被引：0
|
作者：
Park, S.
Lee, S.
Kang, J.
Hwang, I.
Lee, J.
Park, J.
Park, Y.
Lim, H.
Kang, W.
机构：
[1] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[2] Dankook Univ Hosp, Cheonan, South Korea
[3] Gyeongsang Natl Univ Hosp, Jinju, South Korea
[4] Chung Ang Univ, Yong San Hosp, Seoul 156756, South Korea
[5] Soon Chun Hyang Univ Hosp, Seoul, South Korea
[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med, Seoul, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4147
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
    Kohei Shitara
    Keitaro Matsuo
    Kei Muro
    Toshihiko Doi
    Atsushi Ohtsu
    Gastric Cancer, 2014, 17 : 362 - 370
  • [33] Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
    Boeck, S.
    Weigang-Koehler, K.
    Fuchs, M.
    Kettner, E.
    Quietzsch, D.
    Trojan, J.
    Stoetzer, O.
    Zeuzem, S.
    Lordick, F.
    Koehne, C. -H.
    Kroening, H.
    Steinmetz, T.
    Depenbrock, H.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2007, 18 (04) : 745 - 751
  • [34] A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.
    Xu, Rui-hua
    Zhang, Dongsheng
    Shen, Lin
    Li, Jin
    Huang, Jing
    Gong, Jifang
    Guo, Weijian
    Zhang, Yang
    Fan, Songhua
    Li, Ke
    Hua, Ye
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [35] Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy
    Krzakowski, Maciej
    Ramlau, Rodryg
    Jassem, Jacek
    Szczesna, Aleksandra
    Zatloukal, Petr
    Von Pawel, Joachim
    Sun, Xushan
    Bennouna, Jaafar
    Santoro, Armando
    Biesma, Bonne
    Delgado, Francois M.
    Salhi, Yacine
    Vaissiere, Nathalie
    Hansen, Olfred
    Tan, Eng-Huat
    Quoix, Elisabeth
    Garrido, Pilar
    Douillard, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2167 - 2173
  • [36] Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability A Randomized Clinical Trial
    Taieb, Julien
    Bouche, Olivier
    Andre, Thierry
    Le Malicot, Karine
    Laurent-Puig, Pierre
    Bez, Jeremie
    Toullec, Clemence
    Borg, Christophe
    Randrian, Violaine
    Evesque, Ludovic
    Corbinais, Stephane
    Perrier, Herve
    Buecher, Bruno
    Di Fiore, Frederic
    Gallois, Claire
    Emile, Jean Francois
    Lepage, Come
    Elhajbi, Farid
    Tougeron, David
    JAMA ONCOLOGY, 2023, 9 (10) : 1356 - 1363
  • [37] Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial
    Nishikawa, Kazuhiro
    Murotani, Kenta
    Fujitani, Kazumasa
    Inagaki, Hitoshi
    Akamaru, Yusuke
    Tokunaga, Shinya
    Takagi, Masakazu
    Tamura, Shigeyuki
    Sugimoto, Naotoshi
    Shigematsu, Tadashi
    Yoshikawa, Takaki
    Ishiguro, Tohru
    Nakamura, Masato
    Hasegawa, Hiroko
    Morita, Satoshi
    Miyashita, Yumi
    Tsuburaya, Akira
    Sakamoto, Junichi
    Tsujinaka, Toshimasa
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 159 - 167
  • [38] Multivariate prognostic factor analysis to predict survival following second-line chemotherapy in patients with advanced and metastatic gastric cancer
    Catalano, Vincenzo
    Graziano, Francesco
    Santini, Daniele
    D'Emidio, Silvia
    Baldelli, Anna Maria
    Rossi, David
    Vincenzi, Bruno
    Giordani, Paolo
    Testa, Enrica
    Tonini, Giuseppe
    Catalano, Giuseppina
    ANNALS OF ONCOLOGY, 2007, 18 : 8 - 8
  • [39] Exposure–response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
    Tae You Kim
    Chia-Jui Yen
    Salah-Eddin Al-Batran
    David Ferry
    Ling Gao
    Yanzhi Hsu
    Rebecca Cheng
    Mauro Orlando
    Atsushi Ohtsu
    Gastric Cancer, 2018, 21 : 276 - 284
  • [40] Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
    Tabernero, Josep
    Ohtsu, Atsushi
    Muro, Kei
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Ajani, Jaffer A.
    Tomasek, Jiri
    Safran, Howard
    Chandrawansa, Kumari
    Hsu, Yanzhi
    Heathman, Michael
    Khan, Azhar
    Ni, Lan
    Melemed, Allen S.
    Gao, Ling
    Ferry, David
    Fuchs, Charles S.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2215 - 2222
12345